English
简体中文
Total: £ 56.28
Published Date: 2025-09-18 | Pages: 75 | Tables: 71 | Medical Care
The global market for Persistent Epithelial Defect Management was valued at US$ 4612 million in the year 2024 and is projected to reach a revised size of US$ 10251 million by 2031, growing at a CAGR of 12.2% during the forecast period.
With the global aging population and the increasing prevalence of chronic diseases such as diabetes and hypertension, the incidence of PED is rising. Advancements in diagnostic technologies and increased patient awareness have enabled early detection and intervention. Innovations in biologic therapies, stem cell treatments, and regenerative medicine are providing new avenues for PED management.
Despite advancements, PED treatment faces challenges such as high costs and limited accessibility. Therapies like amniotic membrane transplantation and autologous serum eye drops are effective but expensive and may not be readily available in all regions. Additionally, the variability in treatment responses among patients necessitates personalized treatment approaches, which require further research and development.
Patients are increasingly seeking treatments that not only restore vision but also ensure safety and comfort. Non-invasive therapies with minimal side effects, such as ocular biologics and stem cell-based treatments, are gaining popularity. Healthcare providers are focusing on personalized treatment plans to cater to individual patient needs, enhancing therapeutic outcomes and patient satisfaction.
The primary raw materials for PED treatment include amniotic membrane, stem cells, and recombinant growth factors. Amniotic membrane, a biological material, possesses excellent biocompatibility and promotes tissue repair, making it widely used in PED treatment. Stem cells, particularly mesenchymal stem cells, have self-renewal and multi-directional differentiation capabilities, serving as crucial components in PED therapy. Recombinant growth factors, such as recombinant nerve growth factor (rhNGF), play a significant role in promoting the proliferation and migration of corneal epithelial cells.
This report aims to provide a comprehensive presentation of the global market for Persistent Epithelial Defect Management, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Persistent Epithelial Defect Management.
The Persistent Epithelial Defect Management market size, estimations, and forecasts are provided in terms of and revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. This report segments the global Persistent Epithelial Defect Management market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Persistent Epithelial Defect Management companies, new entrants, and industry chain related companies in this market with information on the revenues for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Dompe Farmaceutici
OcuNexus Therapeutics
Eyevance Pharmaceuticals
Noveome Biotherapeutics
RegeneRx Biopharmaceuticals
Recordati Rare Diseases
Mimetech
Johnson & Johnson
Bausch Health
Integra Lifesciences
Segment by Type
Medication
Physical Therapy
Surgery
Other
Segment by Application
Epithelial/Limbal
Inflammatory Disease
Neurotrophic Disease
Others
By Region
North America
U.S.
Canada
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia & New Zealand
Europe
Germany
France
U.K.
Italy
Ireland
Russia
Rest of Europe
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Israel
United Arab Emirates (UAE)
Saudi Arabia
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Persistent Epithelial Defect Management company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
Research Methodology
The research methodology employed has been subjected by numerous procedures in order to guarantee the quality and accuracy of the data contained within the reports. The analysts are employed full-time and received more than six months training to satisfy the standard of our company. Our methodology can be divided into five stages:
★Stage 1 SECONDARY RESEARCH
The research team first collaborates with magazines, trade associations and administrative departments in the research field. The information provided by our internal documentation service is helpful for our further research. Our team has a wealth of experience and knowledge, and can effectively extract accurate information from existing resources.
★Stage 2 PRIMARY RESEARCH:INTERVIEWS WITH TRADE SOURCES
After the first stage, the research team conducts a large number of face-to-face or telephone interviews with representative companies working in the research field. Analysts are trying to have an opportunity to talk to leading companies and small companies in the field. Upstream suppliers, manufacturers, distributors, importers, installers, wholesalers and consumers were included in the interview. The data collected during the interview were then carefully examined and compared with the secondary study.
★Stage 3 ANALYSIS OF THE GATHERED DATA
The analysis team examines and synthesizes the data collected in the first two stages. In order to validate the data, a second round of interviews can be conducted.
★Stage 4 QUANTITATIVE DATA
The quantitative data such as market estimates, production and capacity of manufacturer, market forecasts and investment feasibility is provided by our company. The data is based on the estimates obtained during stage 3.
★Stage 5 QUALITY CONTROL
Before publishing, each report undergoes a rigorous review and editing process, which is done by the experience management team to ensure the reliability of the published data. Every analyst on the research team receives support and continuous training as part of our internal quality process.
1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Persistent Epithelial Defect Management Market Size Growth Rate by Type: 2020 VS 2024 VS 2031
1.2.2 Medication
1.2.3 Physical Therapy
1.2.4 Surgery
1.2.5 Other
1.3 Market by Application
1.3.1 Global Persistent Epithelial Defect Management Market Growth by Application: 2020 VS 2024 VS 2031
1.3.2 Epithelial/Limbal
1.3.3 Inflammatory Disease
1.3.4 Neurotrophic Disease
1.3.5 Others
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Global Growth Trends
2.1 Global Persistent Epithelial Defect Management Market Perspective (2020-2031)
2.2 Global Persistent Epithelial Defect Management Growth Trends by Region
2.2.1 Global Persistent Epithelial Defect Management Market Size by Region: 2020 VS 2024 VS 2031
2.2.2 Persistent Epithelial Defect Management Historic Market Size by Region (2020-2025)
2.2.3 Persistent Epithelial Defect Management Forecasted Market Size by Region (2026-2031)
2.3 Persistent Epithelial Defect Management Market Dynamics
2.3.1 Persistent Epithelial Defect Management Industry Trends
2.3.2 Persistent Epithelial Defect Management Market Drivers
2.3.3 Persistent Epithelial Defect Management Market Challenges
2.3.4 Persistent Epithelial Defect Management Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Persistent Epithelial Defect Management Players by Revenue
3.1.1 Global Top Persistent Epithelial Defect Management Players by Revenue (2020-2025)
3.1.2 Global Persistent Epithelial Defect Management Revenue Market Share by Players (2020-2025)
3.2 Global Top Persistent Epithelial Defect Management Players by Company Type and Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Global Key Players Ranking by Persistent Epithelial Defect Management Revenue
3.4 Global Persistent Epithelial Defect Management Market Concentration Ratio
3.4.1 Global Persistent Epithelial Defect Management Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Persistent Epithelial Defect Management Revenue in 2024
3.5 Global Key Players of Persistent Epithelial Defect Management Head office and Area Served
3.6 Global Key Players of Persistent Epithelial Defect Management, Product and Application
3.7 Global Key Players of Persistent Epithelial Defect Management, Date of Enter into This Industry
3.8 Mergers & Acquisitions, Expansion Plans
4 Persistent Epithelial Defect Management Breakdown Data by Type
4.1 Global Persistent Epithelial Defect Management Historic Market Size by Type (2020-2025)
4.2 Global Persistent Epithelial Defect Management Forecasted Market Size by Type (2026-2031)
5 Persistent Epithelial Defect Management Breakdown Data by Application
5.1 Global Persistent Epithelial Defect Management Historic Market Size by Application (2020-2025)
5.2 Global Persistent Epithelial Defect Management Forecasted Market Size by Application (2026-2031)
6 North America
6.1 North America Persistent Epithelial Defect Management Market Size (2020-2031)
6.2 North America Persistent Epithelial Defect Management Market Growth Rate by Country: 2020 VS 2024 VS 2031
6.3 North America Persistent Epithelial Defect Management Market Size by Country (2020-2025)
6.4 North America Persistent Epithelial Defect Management Market Size by Country (2026-2031)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Persistent Epithelial Defect Management Market Size (2020-2031)
7.2 Europe Persistent Epithelial Defect Management Market Growth Rate by Country: 2020 VS 2024 VS 2031
7.3 Europe Persistent Epithelial Defect Management Market Size by Country (2020-2025)
7.4 Europe Persistent Epithelial Defect Management Market Size by Country (2026-2031)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Ireland
8 Asia-Pacific
8.1 Asia-Pacific Persistent Epithelial Defect Management Market Size (2020-2031)
8.2 Asia-Pacific Persistent Epithelial Defect Management Market Growth Rate by Region: 2020 VS 2024 VS 2031
8.3 Asia-Pacific Persistent Epithelial Defect Management Market Size by Region (2020-2025)
8.4 Asia-Pacific Persistent Epithelial Defect Management Market Size by Region (2026-2031)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia & New Zealand
9 Latin America
9.1 Latin America Persistent Epithelial Defect Management Market Size (2020-2031)
9.2 Latin America Persistent Epithelial Defect Management Market Growth Rate by Country: 2020 VS 2024 VS 2031
9.3 Latin America Persistent Epithelial Defect Management Market Size by Country (2020-2025)
9.4 Latin America Persistent Epithelial Defect Management Market Size by Country (2026-2031)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Persistent Epithelial Defect Management Market Size (2020-2031)
10.2 Middle East & Africa Persistent Epithelial Defect Management Market Growth Rate by Country: 2020 VS 2024 VS 2031
10.3 Middle East & Africa Persistent Epithelial Defect Management Market Size by Country (2020-2025)
10.4 Middle East & Africa Persistent Epithelial Defect Management Market Size by Country (2026-2031)
10.5 Israel
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Dompe Farmaceutici
11.1.1 Dompe Farmaceutici Company Details
11.1.2 Dompe Farmaceutici Business Overview
11.1.3 Dompe Farmaceutici Persistent Epithelial Defect Management Introduction
11.1.4 Dompe Farmaceutici Revenue in Persistent Epithelial Defect Management Business (2020-2025)
11.1.5 Dompe Farmaceutici Recent Development
11.2 OcuNexus Therapeutics
11.2.1 OcuNexus Therapeutics Company Details
11.2.2 OcuNexus Therapeutics Business Overview
11.2.3 OcuNexus Therapeutics Persistent Epithelial Defect Management Introduction
11.2.4 OcuNexus Therapeutics Revenue in Persistent Epithelial Defect Management Business (2020-2025)
11.2.5 OcuNexus Therapeutics Recent Development
11.3 Eyevance Pharmaceuticals
11.3.1 Eyevance Pharmaceuticals Company Details
11.3.2 Eyevance Pharmaceuticals Business Overview
11.3.3 Eyevance Pharmaceuticals Persistent Epithelial Defect Management Introduction
11.3.4 Eyevance Pharmaceuticals Revenue in Persistent Epithelial Defect Management Business (2020-2025)
11.3.5 Eyevance Pharmaceuticals Recent Development
11.4 Noveome Biotherapeutics
11.4.1 Noveome Biotherapeutics Company Details
11.4.2 Noveome Biotherapeutics Business Overview
11.4.3 Noveome Biotherapeutics Persistent Epithelial Defect Management Introduction
11.4.4 Noveome Biotherapeutics Revenue in Persistent Epithelial Defect Management Business (2020-2025)
11.4.5 Noveome Biotherapeutics Recent Development
11.5 RegeneRx Biopharmaceuticals
11.5.1 RegeneRx Biopharmaceuticals Company Details
11.5.2 RegeneRx Biopharmaceuticals Business Overview
11.5.3 RegeneRx Biopharmaceuticals Persistent Epithelial Defect Management Introduction
11.5.4 RegeneRx Biopharmaceuticals Revenue in Persistent Epithelial Defect Management Business (2020-2025)
11.5.5 RegeneRx Biopharmaceuticals Recent Development
11.6 Recordati Rare Diseases
11.6.1 Recordati Rare Diseases Company Details
11.6.2 Recordati Rare Diseases Business Overview
11.6.3 Recordati Rare Diseases Persistent Epithelial Defect Management Introduction
11.6.4 Recordati Rare Diseases Revenue in Persistent Epithelial Defect Management Business (2020-2025)
11.6.5 Recordati Rare Diseases Recent Development
11.7 Mimetech
11.7.1 Mimetech Company Details
11.7.2 Mimetech Business Overview
11.7.3 Mimetech Persistent Epithelial Defect Management Introduction
11.7.4 Mimetech Revenue in Persistent Epithelial Defect Management Business (2020-2025)
11.7.5 Mimetech Recent Development
11.8 Johnson & Johnson
11.8.1 Johnson & Johnson Company Details
11.8.2 Johnson & Johnson Business Overview
11.8.3 Johnson & Johnson Persistent Epithelial Defect Management Introduction
11.8.4 Johnson & Johnson Revenue in Persistent Epithelial Defect Management Business (2020-2025)
11.8.5 Johnson & Johnson Recent Development
11.9 Bausch Health
11.9.1 Bausch Health Company Details
11.9.2 Bausch Health Business Overview
11.9.3 Bausch Health Persistent Epithelial Defect Management Introduction
11.9.4 Bausch Health Revenue in Persistent Epithelial Defect Management Business (2020-2025)
11.9.5 Bausch Health Recent Development
11.10 Integra Lifesciences
11.10.1 Integra Lifesciences Company Details
11.10.2 Integra Lifesciences Business Overview
11.10.3 Integra Lifesciences Persistent Epithelial Defect Management Introduction
11.10.4 Integra Lifesciences Revenue in Persistent Epithelial Defect Management Business (2020-2025)
11.10.5 Integra Lifesciences Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.1.1 Research Programs/Design
13.1.1.2 Market Size Estimation
13.1.1.3 Market Breakdown and Data Triangulation
13.1.2 Data Source
13.1.2.1 Secondary Sources
13.1.2.2 Primary Sources
13.2 Author Details
13.3 Disclaimer
List of Tables
Table 1. Global Persistent Epithelial Defect Management Market Size Growth Rate by Type (US$ Million): 2020 VS 2024 VS 2031
Table 2. Key Players of Medication
Table 3. Key Players of Physical Therapy
Table 4. Key Players of Surgery
Table 5. Key Players of Other
Table 6. Global Persistent Epithelial Defect Management Market Size Growth by Application (US$ Million): 2020 VS 2024 VS 2031
Table 7. Global Persistent Epithelial Defect Management Market Size by Region (US$ Million): 2020 VS 2024 VS 2031
Table 8. Global Persistent Epithelial Defect Management Market Size by Region (2020-2025) & (US$ Million)
Table 9. Global Persistent Epithelial Defect Management Market Share by Region (2020-2025)
Table 10. Global Persistent Epithelial Defect Management Forecasted Market Size by Region (2026-2031) & (US$ Million)
Table 11. Global Persistent Epithelial Defect Management Market Share by Region (2026-2031)
Table 12. Persistent Epithelial Defect Management Market Trends
Table 13. Persistent Epithelial Defect Management Market Drivers
Table 14. Persistent Epithelial Defect Management Market Challenges
Table 15. Persistent Epithelial Defect Management Market Restraints
Table 16. Global Persistent Epithelial Defect Management Revenue by Players (2020-2025) & (US$ Million)
Table 17. Global Persistent Epithelial Defect Management Market Share by Players (2020-2025)
Table 18. Global Top Persistent Epithelial Defect Management Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Persistent Epithelial Defect Management as of 2024)
Table 19. Ranking of Global Top Persistent Epithelial Defect Management Companies by Revenue (US$ Million) in 2024
Table 20. Global 5 Largest Players Market Share by Persistent Epithelial Defect Management Revenue (CR5 and HHI) & (2020-2025)
Table 21. Global Key Players of Persistent Epithelial Defect Management, Headquarters and Area Served
Table 22. Global Key Players of Persistent Epithelial Defect Management, Product and Application
Table 23. Global Key Players of Persistent Epithelial Defect Management, Date of Enter into This Industry
Table 24. Mergers & Acquisitions, Expansion Plans
Table 25. Global Persistent Epithelial Defect Management Market Size by Type (2020-2025) & (US$ Million)
Table 26. Global Persistent Epithelial Defect Management Revenue Market Share by Type (2020-2025)
Table 27. Global Persistent Epithelial Defect Management Forecasted Market Size by Type (2026-2031) & (US$ Million)
Table 28. Global Persistent Epithelial Defect Management Revenue Market Share by Type (2026-2031)
Table 29. Global Persistent Epithelial Defect Management Market Size by Application (2020-2025) & (US$ Million)
Table 30. Global Persistent Epithelial Defect Management Revenue Market Share by Application (2020-2025)
Table 31. Global Persistent Epithelial Defect Management Forecasted Market Size by Application (2026-2031) & (US$ Million)
Table 32. Global Persistent Epithelial Defect Management Revenue Market Share by Application (2026-2031)
Table 33. North America Persistent Epithelial Defect Management Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
Table 34. North America Persistent Epithelial Defect Management Market Size by Country (2020-2025) & (US$ Million)
Table 35. North America Persistent Epithelial Defect Management Market Size by Country (2026-2031) & (US$ Million)
Table 36. Europe Persistent Epithelial Defect Management Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
Table 37. Europe Persistent Epithelial Defect Management Market Size by Country (2020-2025) & (US$ Million)
Table 38. Europe Persistent Epithelial Defect Management Market Size by Country (2026-2031) & (US$ Million)
Table 39. Asia-Pacific Persistent Epithelial Defect Management Market Size Growth Rate by Region (US$ Million): 2020 VS 2024 VS 2031
Table 40. Asia-Pacific Persistent Epithelial Defect Management Market Size by Region (2020-2025) & (US$ Million)
Table 41. Asia-Pacific Persistent Epithelial Defect Management Market Size by Region (2026-2031) & (US$ Million)
Table 42. Latin America Persistent Epithelial Defect Management Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
Table 43. Latin America Persistent Epithelial Defect Management Market Size by Country (2020-2025) & (US$ Million)
Table 44. Latin America Persistent Epithelial Defect Management Market Size by Country (2026-2031) & (US$ Million)
Table 45. Middle East & Africa Persistent Epithelial Defect Management Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
Table 46. Middle East & Africa Persistent Epithelial Defect Management Market Size by Country (2020-2025) & (US$ Million)
Table 47. Middle East & Africa Persistent Epithelial Defect Management Market Size by Country (2026-2031) & (US$ Million)
Table 48. Dompe Farmaceutici Company Details
Table 49. Dompe Farmaceutici Business Overview
Table 50. Dompe Farmaceutici Persistent Epithelial Defect Management Product
Table 51. Dompe Farmaceutici Revenue in Persistent Epithelial Defect Management Business (2020-2025) & (US$ Million)
Table 52. Dompe Farmaceutici Recent Development
Table 53. OcuNexus Therapeutics Company Details
Table 54. OcuNexus Therapeutics Business Overview
Table 55. OcuNexus Therapeutics Persistent Epithelial Defect Management Product
Table 56. OcuNexus Therapeutics Revenue in Persistent Epithelial Defect Management Business (2020-2025) & (US$ Million)
Table 57. OcuNexus Therapeutics Recent Development
Table 58. Eyevance Pharmaceuticals Company Details
Table 59. Eyevance Pharmaceuticals Business Overview
Table 60. Eyevance Pharmaceuticals Persistent Epithelial Defect Management Product
Table 61. Eyevance Pharmaceuticals Revenue in Persistent Epithelial Defect Management Business (2020-2025) & (US$ Million)
Table 62. Eyevance Pharmaceuticals Recent Development
Table 63. Noveome Biotherapeutics Company Details
Table 64. Noveome Biotherapeutics Business Overview
Table 65. Noveome Biotherapeutics Persistent Epithelial Defect Management Product
Table 66. Noveome Biotherapeutics Revenue in Persistent Epithelial Defect Management Business (2020-2025) & (US$ Million)
Table 67. Noveome Biotherapeutics Recent Development
Table 68. RegeneRx Biopharmaceuticals Company Details
Table 69. RegeneRx Biopharmaceuticals Business Overview
Table 70. RegeneRx Biopharmaceuticals Persistent Epithelial Defect Management Product
Table 71. RegeneRx Biopharmaceuticals Revenue in Persistent Epithelial Defect Management Business (2020-2025) & (US$ Million)
Table 72. RegeneRx Biopharmaceuticals Recent Development
Table 73. Recordati Rare Diseases Company Details
Table 74. Recordati Rare Diseases Business Overview
Table 75. Recordati Rare Diseases Persistent Epithelial Defect Management Product
Table 76. Recordati Rare Diseases Revenue in Persistent Epithelial Defect Management Business (2020-2025) & (US$ Million)
Table 77. Recordati Rare Diseases Recent Development
Table 78. Mimetech Company Details
Table 79. Mimetech Business Overview
Table 80. Mimetech Persistent Epithelial Defect Management Product
Table 81. Mimetech Revenue in Persistent Epithelial Defect Management Business (2020-2025) & (US$ Million)
Table 82. Mimetech Recent Development
Table 83. Johnson & Johnson Company Details
Table 84. Johnson & Johnson Business Overview
Table 85. Johnson & Johnson Persistent Epithelial Defect Management Product
Table 86. Johnson & Johnson Revenue in Persistent Epithelial Defect Management Business (2020-2025) & (US$ Million)
Table 87. Johnson & Johnson Recent Development
Table 88. Bausch Health Company Details
Table 89. Bausch Health Business Overview
Table 90. Bausch Health Persistent Epithelial Defect Management Product
Table 91. Bausch Health Revenue in Persistent Epithelial Defect Management Business (2020-2025) & (US$ Million)
Table 92. Bausch Health Recent Development
Table 93. Integra Lifesciences Company Details
Table 94. Integra Lifesciences Business Overview
Table 95. Integra Lifesciences Persistent Epithelial Defect Management Product
Table 96. Integra Lifesciences Revenue in Persistent Epithelial Defect Management Business (2020-2025) & (US$ Million)
Table 97. Integra Lifesciences Recent Development
Table 98. Research Programs/Design for This Report
Table 99. Key Data Information from Secondary Sources
Table 100. Key Data Information from Primary Sources
Table 101. Authors List of This Report
List of Figures
Figure 1. Persistent Epithelial Defect Management Picture
Figure 2. Global Persistent Epithelial Defect Management Market Size Comparison by Type (2020-2031) & (US$ Million)
Figure 3. Global Persistent Epithelial Defect Management Market Share by Type: 2024 VS 2031
Figure 4. Medication Features
Figure 5. Physical Therapy Features
Figure 6. Surgery Features
Figure 7. Other Features
Figure 8. Global Persistent Epithelial Defect Management Market Size by Application (2020-2031) & (US$ Million)
Figure 9. Global Persistent Epithelial Defect Management Market Share by Application: 2024 VS 2031
Figure 10. Epithelial/Limbal Case Studies
Figure 11. Inflammatory Disease Case Studies
Figure 12. Neurotrophic Disease Case Studies
Figure 13. Others Case Studies
Figure 14. Persistent Epithelial Defect Management Report Years Considered
Figure 15. Global Persistent Epithelial Defect Management Market Size (US$ Million), Year-over-Year: 2020-2031
Figure 16. Global Persistent Epithelial Defect Management Market Size, (US$ Million), 2020 VS 2024 VS 2031
Figure 17. Global Persistent Epithelial Defect Management Market Share by Region: 2024 VS 2031
Figure 18. Global Persistent Epithelial Defect Management Market Share by Players in 2024
Figure 19. Global Persistent Epithelial Defect Management Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
Figure 20. The Top 10 and 5 Players Market Share by Persistent Epithelial Defect Management Revenue in 2024
Figure 21. North America Persistent Epithelial Defect Management Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 22. North America Persistent Epithelial Defect Management Market Share by Country (2020-2031)
Figure 23. United States Persistent Epithelial Defect Management Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 24. Canada Persistent Epithelial Defect Management Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 25. Europe Persistent Epithelial Defect Management Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 26. Europe Persistent Epithelial Defect Management Market Share by Country (2020-2031)
Figure 27. Germany Persistent Epithelial Defect Management Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 28. France Persistent Epithelial Defect Management Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 29. U.K. Persistent Epithelial Defect Management Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 30. Italy Persistent Epithelial Defect Management Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 31. Russia Persistent Epithelial Defect Management Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 32. Ireland Persistent Epithelial Defect Management Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 33. Asia-Pacific Persistent Epithelial Defect Management Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 34. Asia-Pacific Persistent Epithelial Defect Management Market Share by Region (2020-2031)
Figure 35. China Persistent Epithelial Defect Management Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 36. Japan Persistent Epithelial Defect Management Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 37. South Korea Persistent Epithelial Defect Management Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 38. Southeast Asia Persistent Epithelial Defect Management Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 39. India Persistent Epithelial Defect Management Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 40. Australia & New Zealand Persistent Epithelial Defect Management Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 41. Latin America Persistent Epithelial Defect Management Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 42. Latin America Persistent Epithelial Defect Management Market Share by Country (2020-2031)
Figure 43. Mexico Persistent Epithelial Defect Management Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 44. Brazil Persistent Epithelial Defect Management Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 45. Middle East & Africa Persistent Epithelial Defect Management Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 46. Middle East & Africa Persistent Epithelial Defect Management Market Share by Country (2020-2031)
Figure 47. Israel Persistent Epithelial Defect Management Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 48. Saudi Arabia Persistent Epithelial Defect Management Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 49. UAE Persistent Epithelial Defect Management Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 50. Dompe Farmaceutici Revenue Growth Rate in Persistent Epithelial Defect Management Business (2020-2025)
Figure 51. OcuNexus Therapeutics Revenue Growth Rate in Persistent Epithelial Defect Management Business (2020-2025)
Figure 52. Eyevance Pharmaceuticals Revenue Growth Rate in Persistent Epithelial Defect Management Business (2020-2025)
Figure 53. Noveome Biotherapeutics Revenue Growth Rate in Persistent Epithelial Defect Management Business (2020-2025)
Figure 54. RegeneRx Biopharmaceuticals Revenue Growth Rate in Persistent Epithelial Defect Management Business (2020-2025)
Figure 55. Recordati Rare Diseases Revenue Growth Rate in Persistent Epithelial Defect Management Business (2020-2025)
Figure 56. Mimetech Revenue Growth Rate in Persistent Epithelial Defect Management Business (2020-2025)
Figure 57. Johnson & Johnson Revenue Growth Rate in Persistent Epithelial Defect Management Business (2020-2025)
Figure 58. Bausch Health Revenue Growth Rate in Persistent Epithelial Defect Management Business (2020-2025)
Figure 59. Integra Lifesciences Revenue Growth Rate in Persistent Epithelial Defect Management Business (2020-2025)
Figure 60. Bottom-up and Top-down Approaches for This Report
Figure 61. Data Triangulation
Figure 62. Key Executives Interviewed
